Drugs / Casigold
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT00471263 | May → Dec 2007 | hypertensive disorder | TNO | Completed | Met primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Casigold | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00471263 ↗ |
| Action | Inhibit | “which have ACE inhibitory properties in vitro” NCT00471263 ↗ |
| Modality | Peptide | “CasiGold and CasiMax are hydrolysed casein preparations consisting of relatively high concentrations tripeptides” NCT00471263 ↗ |
| Route | Oral | “daily consumption of two capsules Casigold containing IPP” NCT00471263 ↗ |
| Target | ACE | “which have ACE inhibitory properties in vitro” NCT00471263 ↗ |